Fed’s Powell opens door to potential rate cuts at Jackson Hole
Monogram Technologies Inc. (NASDAQ:MGRM) on Monday released a set of frequently asked questions to its shareholders concerning the company’s proposed acquisition by Zimmer Biomet Holdings (NYSE:ZBH), Inc. The FAQs were distributed to address shareholder inquiries about the transaction, which was originally announced on July 14.
According to a statement included in a regulatory filing with the Securities and Exchange Commission, the company provided this information as part of its ongoing communications with shareholders about the pending deal. The full text of the FAQs was attached as an exhibit to the filing.
The filing did not contain additional details regarding the terms of the acquisition or any changes to the previously announced transaction. Monogram Technologies’ common stock continues to trade on The Nasdaq Stock Market under the symbol MGRM.
This article is based on a press release statement filed with the SEC.
In other recent news, Monogram Technologies Inc. announced the termination of its Exclusive License Agreement with the Icahn School of Medicine at Mount Sinai. As part of the settlement, Monogram will pay Mount Sinai $4 million, including $500,000 in cash and 35,000 shares of Series E Redeemable Perpetual Preferred Stock. In a significant development, Zimmer Biomet has entered into a definitive agreement to acquire Monogram Technologies for approximately $177 million in equity value. Monogram stockholders will receive $4.04 per share in cash, along with a contingent value right that could provide up to $12.37 per share if certain milestones are met by 2030. Additionally, Monogram has announced the mandatory conversion of all outstanding shares of its Series D Convertible Cumulative Preferred Stock. The company also reported its first-quarter financial results for 2025, with an earnings per share forecast of -0.11, though no actual EPS data was provided. These recent developments highlight Monogram’s strategic shifts and financial activities in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.